Pivotal bioVenture Partners Fund I, L.P. - Jul 1, 2025 SCHEDULE 13D/A Report for Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY)

Reporting Managers (10)

Name	Ownership	Signature	Title	CIK
Pivotal bioVenture Partners Fund I, L.P.	0%	/s/ Robert Hopfner, Director	By Pivotal bioVenture Partners Fund I G.P., L.P., its general partner; by Pivotal bioVenture Partners Fund I U.G.P. Ltd, its general partner	0001695076
Pivotal bioVenture Partners Fund II, L.P.	0%	/s/ Peter Tuxen Bisgaard	By Pivotal bioVenture Partners Fund II G.P., Ltd, its general partner; By Peter Tuxen Bisgaard, Director	0001857522
Pivotal bioVenture Partners Fund II G.P. Ltd	0%	/s/ Peter Tuxen Bisgaard	Peter Tuxen Bisgaard, Director
Pivotal bioVenture Partners Fund I G.P., L.P.	0%	/s/ Robert Hopfner	By Pivotal bioVenture Partners Fund I U.G.P. Ltd, its general partner; By Robert Hopfner, Authorized Signatory	0001752862
Pivotal bioVenture Partners Fund I U.G.P. Ltd	0%	/s/ Robert Hopfner	Robert Hopfner, Authorized Signatory	0001752847
Pivotal Partners Ltd	0%	/s/ Sun Xintong	Sun Xintong, Director
Pivotal Life Sciences Holdings Limited	0%	/s/ Sun Xintong	Sun Xintong, Director
Nan Fung Life Sciences Holdings Limited	0%	/s/ Sun Xintong	Sun Xintong, Director
NF Investment Holdings Limited	0%	/s/ Tang Chun Wai Nelson	Tang Chun Wai Nelson, Director
Nan Fung Group Holdings Limited	0%	/s/ Tang Chun Wai Nelson	Tang Chun Wai Nelson, Director	0001782539